ASTERO

Manufacturer
Lake Erie Medical DBA Quality Care Products LLC
Effective date
2021-04-15
Label type
PRESCRIPTION MEDICAL DEVICE LABEL
Version
8
Source
legacy-cache
Hydrated at
2026-08-01 22:47:15

Label at a glance#

ProductASTERO
Active ingredientLIDOCAINE
Label structure11 sections

Indications and uses

Astero™ is a medicated Hydrogel wound dressing in a Metered Dose (M-DOSE™) bottle containing lidocaine 4%, an amide type local anesthetic, indicated for: Painful wounds such as post-surgicalincisions, cuts and abrasions.

Dosage and administration

Cleanse the wound and blow it dry. Apply a thin layer of ASTERO to the wound surface and the skin immediately surrounding the wound 3-4 times daily.

Storage and handling

Store at 25ºC (77ºF); excursions permitted to 15º-30ºC (59º-86º F). See USP Controlled Room Temperature. Protect from freezing.

Label contents#

Full prescribing information#

SPL UNCLASSIFIED SECTION

Rx only

DO NOT USE IN THE EYES.

DESCRIPTION

DESCRIPTION SECTION

A soothing hydrogel wound dressing that promotes a moist wound environment that is ideal for the healing process

ASTERO contains Lidocaine HCl USP 4%, which is chemically designated as acetamide, 2-(diethylamino)-N-(2,6-dimethylphenyl)-, and has the following structural formula:

Lidocaine structure
Lidocaine structure

INDICATIONS AND USAGE

INDICATIONS & USAGE SECTION

Astero™ is a medicated Hydrogel wound dressing in a Metered Dose (M-DOSE™) bottle containing lidocaine 4%, an amide type local anesthetic, indicated for:
Painful wounds such as post-surgicalincisions, cuts and abrasions.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

Traumatized mucosa, secondary bacterial infection of the area of proposed application and known hypersensitivity to any of the components.

Lidocaine Hydrochloride USP is contraindicated in patients with a known history of hypersensitivity to local anesthetics of the amide type.

WARNINGS

WARNINGS SECTION

Do not use this product if you are allergic to any ingredients. If condition worsens or does not improve within 7 days, consult a physician. Do not use on children under 2 years of age without consulting a physician.
Avoid contact with eyes. Do not use in large quantities.

For external use only.Avoid Contact with Eyes.
Keep out of reach of children.

PRECAUTIONS

PRECAUTIONS SECTION

If irritation or sensitivity occurs or infection appears, discontinue use and institute appropriate therapy. Astero should be used with caution in ill, elderly, debilitated patients and children who may be more sensitive to the systemic effects of Lidocaine Hydrochloride USP.

CARCINOGENESIS, MUTAGENESIS, AND IMPAIRMENT OF FERTILITY

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Studies of Lidocaine Hydrochloride USP in animals to evaluate the carcinogenic and mutagenic potential or the effect on fertility have not been conducted.

USE IN PREGNANCY

PREGNANCY SECTION

Teratogenic Effects:

TERATOGENIC EFFECTS SECTION

Teratogenic Effects of Lidocaine Hydrochloride USP. Pregnancy Category B. Reproduction studies have been performed in rats at doses up to 6.6 times the human dose and have revealed no evidence of harm to the fetus caused by Lidocaine Hydrochloride USP. There are, however, no adequate and well-controlled studies in pregnant women. Animal reproduction studies are not always predictive of human response. General consideration should be given to this fact before administering Lidocaine Hydrochloride USP to women of childbearing potential, especially during early pregnancy when maximum organogenesis takes place.

NURSING MOTHERS:

NURSING MOTHERS SECTION

Lidocaine Hydrochloride USP is not contraindicated in labor and delivery. Should Astero be used concomitantly with other products containing Lidocaine Hydrochloride USP, the total dose contributed by all formulations must be kept in mind.

PEDIATRIC USE:

PEDIATRIC USE SECTION

Dosage in children should be reduced, commensurate with age, body weight and physical condition. Caution must be taken to avoid over dosage when applying Astero to large areas of injured or abraded skin, since the systemic absorption of Lidocaine Hydrochloride USP may be increased under such conditions. Do not use on children under 2 unless directed by a physician.

ADVERSE REACTIONS:

ADVERSE REACTIONS SECTION

Adverse experiences following the administration of Lidocaine Hydrochloride USP are similar in nature to those observed with other amide local anesthetic agents. These adverse experiences are, in general, dose-related and may result from high plasma levels caused by excessive dosage or rapid absorption, or may result from a hypersensitivity, idiosyncrasy or diminished tolerance on the part of the patient.
Serious adverse experiences are generally systemic in nature. The following types are those most commonly reported:

Central Nervous System:

SPL UNCLASSIFIED SECTION

CNS manifestations of Lidocaine toxicity are excitatory and/or depressant and may be characterized by lightheadedness, nervousness, apprehension, euphoria, confusion, dizziness, drowsiness, tinnitus, blurred or double vision, vomiting, sensations of heat, cold or numbness, twitching, tremors, convulsions, unconsciousness, respiratory depression and arrest. The excitatory manifestations may be very brief or may not occur at all, in which case the first manifestation of toxicity may be drowsiness merging into unconsciousness and respiratory arrest. Drowsiness following the administration of Lidocaine Hydrochloride USP is usually an early sign of a high blood level of the drug and may occur as a consequence of rapid absorption.

Cardiovascular system

SPL UNCLASSIFIED SECTION

Cardiovascular manifestations of Lidocaine toxicity are usually depressant and are characterized by bradycardia, hypotension, and cardiovascular collapse, which may lead to cardiac arrest.

Allergic

SPL UNCLASSIFIED SECTION

Allergic reactions are characterized by cutaneous lesions, urticaria, edema or anaphylactoid reactions. Allergic reactions may occur as a result of sensitivity either to the local anesthetic agent or to other components in the formulation. Allergic reactions as a result of sensitivity to Lidocaine Hydrochloride USP are extremely rare and, if they occur, should be managed by conventional means. The detection of sensitivity by skin testing is of doubtful value.

DOSAGE AND ADMINISTRATION:

DOSAGE & ADMINISTRATION SECTION

Administration

SPL UNCLASSIFIED SECTION

Cleanse the wound and blow it dry. Apply a thin layer of ASTERO to the wound surface and the skin immediately surrounding the wound 3-4 times daily.

STORAGE AND HANDLING

STORAGE AND HANDLING SECTION

Store at 25ºC (77ºF); excursions permitted to 15º-30ºC (59º-86º F). See USP Controlled Room Temperature. Protect from freezing.

HOW SUPPLIED

HOW SUPPLIED SECTION

ASTERO (Lidocaine HCl USP 4%)

1.0 oz (28.5g) 30mL Airless Pump - NDC 35781-2500-3

Gensco Labratories, LLC
8550 NW 33rd St Suite 200
Doral, FL 33122

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

image descriptionimage description

DailyMed Billing Units#

Package NDC, Billing unit, Product NDC table
Package NDCBilling unitProduct NDCDailyMed indexing SPLSPL versionEffective
55700-421-30ML - Milliliter55700-42113fceecf-b61e-4c2c-812b-63396d27be6212016-11-08
55700-421-90ML - Milliliter55700-421706527f1-cc3f-4e79-881c-c58ac22c8ca612019-08-06
35781-2500-3ML - Milliliter35781-250040ac8974-4f6f-4785-97cb-9e861086184912016-07-19
35781-2500-9ML - Milliliter35781-25002cc96780-d486-473e-9c44-c5800ac37dba12019-10-07

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 8 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
55700-42155700-421-30, 55700-421-90
35781-2500

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 7 matching rows.

Source Document#

Source XML · Source PDF

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 25 · 499 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
Lidocaine Pain Relief Gel-PatchLIDOCAINEGuangzhou Dachuang International Trade Co., Ltd5f849516-16d0-6905-e063-6294a90a20302026-11-05WarningsName fallback
generic name: LIDOCAINE
CVS Flex Pain Relief LidocaineLIDOCAINECVS Pharmacy58cb50b7-751b-4a8d-e063-6394a90a0fd92026-11-05WarningsName fallback
generic name: LIDOCAINE
Lidocaine Roll-onLIDOCAINEYYBA Corp5f8a807b-1ea2-ea69-e063-6294a90a32072026-11-05WarningsName fallback
generic name: LIDOCAINE
Lidocaine 4% Maximum OTC StrengthLIDOCAINECardinal Health 107, LLC975031df-d46d-4098-b1c0-1c0c92b419952026-11-04WarningsName fallback
generic name: LIDOCAINE
MERRINGTON 4% LIDOCAINE PAIN RELIEFLIDOCAINEMERRINGTON, INC.ae5b8e00-3c3c-4e7d-a0f9-2937fec01a7b2026-11-04WarningsName fallback
generic name: LIDOCAINE
Lidocaine Pain Relief Gel-PatchLIDOCAINEGuangzhou Zhupuyou E-commerce Co., Ltd296fcc36-563f-19ca-e063-6394a90ab3ae2026-11-03WarningsName fallback
generic name: LIDOCAINE
Welmate Lidocaine Pain Relieving PatchLIDOCAINEYYBA CORP4303fd30-0d35-3671-e063-6394a90a2aee2026-11-02WarningsName fallback
generic name: LIDOCAINE
Lidocaine HydrochlorideLIDOCAINEHenry Schein, Inc.0c0790ec-effd-4d8a-9874-8ca0b31e54d02026-11-02Warnings, Adverse reactionsName fallback
generic name: LIDOCAINE
LidocaineLIDOCAINEREMEDYREPACK INC.0748b9e3-1247-4eeb-8158-3d641b2ad85d2026-10-29Warnings, Adverse reactionsName fallback
generic name: LIDOCAINE
Coralite Odor Free Pain ReliefLIDOCAINEUnited Exchange Corporation7966d9f2-22f9-a900-e053-2991aa0aba552026-10-28WarningsName fallback
generic name: LIDOCAINE
Foot and Leg Pain ReliefLIDOCAINEPremier Brands of America Inc.42f23e2f-11c6-da49-e063-6294a90ac7202026-10-28WarningsName fallback
generic name: LIDOCAINE
Xesso Rear Comfort GlideLIDOCAINEPremium Natural Cosmetics Incc288d55c-6a78-01b0-e053-2995a90a7cad2026-10-27WarningsName fallback
generic name: LIDOCAINE
Lidocaine Pain Relief PatchLIDOCAINEGERI-CARE PHARMACEUTICAL CORP51b7753b-8619-6ea9-e063-6294a90a4ea42026-10-26WarningsName fallback
generic name: LIDOCAINE
NO MORE PELIDOCAINEMUHAMMAD SABIH JAVED738fb047-fdfa-4916-9c0c-010951a70f702026-10-22WarningsName fallback
generic name: LIDOCAINE
Lidocaine Pain Relief Gel-PatchLIDOCAINEGuangzhou Dachuang International Trade Co., Ltd5e2a4bb8-a4eb-8b31-e063-6294a90a41a02026-10-18WarningsName fallback
generic name: LIDOCAINE
lidocaineLIDOCAINEREMEDYREPACK INC.499b4443-7aed-4ac5-ab16-f47e759c32012026-10-16Warnings, Adverse reactionsName fallback
generic name: LIDOCAINE
Lidocaine Pain Relief Gel -PatchLIDOCAINEGuangzhou Liuquanmiao Import & Export Trade Co., Ltd.51d32d7c-3ba7-81cd-e063-6294a90a20412026-10-14WarningsName fallback
generic name: LIDOCAINE
Salonpas Pain Relieving LIDOCAINE 4% FLEXLIDOCAINEHisamitsu Pharmaceutical Co., Inc.9507f727-c49f-4de4-9d64-b6d977d568ab2026-10-14WarningsName fallback
generic name: LIDOCAINE
Lidocaine Pain Relief Gel-PatchLIDOCAINEGuangzhou Dachuang International Trade Co., Ltd5dc4baf4-6f96-fc67-e063-6394a90a4b8a2026-10-13WarningsName fallback
generic name: LIDOCAINE
LidocannaLIDOCAINEPHARMACURE LLCb28ebbb6-1112-4750-a2bb-f96b03fabe6e2026-10-09WarningsName fallback
generic name: LIDOCAINE

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.